NCT02780323View on ClinicalTrials.gov

Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL

Enrollment

119

Participants

Timeline

Start Date

November 2, 2015

Primary Completion Date

December 26, 2017

Study Completion Date

December 26, 2017

Conditions

Rheumatoid Arthritis

Interventions

DRUG

CELBESTA®

1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks

DRUG

CELEBREX®

1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks

DRUG

CELEBREX® placebo

1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks

DRUG

CELBESTA® placebo

1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks

Trial Locations (1)

130-702

Kyung Hee University Hospital, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT02780323 - Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter